7.5 Gy×2次方案在术后子宫内膜癌单纯阴道近距离放疗中是否比6 Gy×3次更高效?一项临床与剂量学分析
本研究比较110例术后子宫内膜癌患者接受单纯高剂量率阴道近距离放疗两种方案的阴道残端复发、晚期毒性、剂量学及阴道扩张器使用情况。组1为44例接受6 Gy×3次,组2为66例接受7.5 Gy×2次且CTV最暴露2 cm³的EQD2(α/β=3)限量为68 Gy。两组均无阴道残端复发及膀胱、直肠晚期毒性,组1阴道晚期毒性≥G1为26/44(59.1%),组2为25/66(37.9%)。作者认为7.5 Gy×2次在患者舒适度、工作量和成本方面似乎更高效,但需更大样本证实。
要点
- 两组均无阴道残端复发及膀胱、直肠晚期毒性。
- 阴道晚期毒性≥G1:组1为26/44(59.1%),组2为25/66(37.9%)。
- CTV最暴露2 cm³平均EQD2(α/β=3):组1为63.7 Gy±10.0,组2为60.5 Gy±3.8(p=0.063)。
核心结论
- 考虑到无阴道复发且阴道晚期毒性随时间相似,7.5 Gy×2次方案在患者舒适度、工作量和成本方面似乎更高效。
- 这是首项使用剂量学参数比较方案有效性的研究,需更大样本系列证实当前结果。
研究设计与样本
- 研究纳入110例术后子宫内膜癌患者,接受单纯高剂量率阴道近距离放疗。
- 组1为44例,接受6 Gy×3次(2011年9月至2014年4月)。
- 组2为66例,接受7.5 Gy×2次,CTV最暴露2 cm³的EQD2(α/β=3)剂量限量为68 Gy(2015年7月至2021年11月)。
- 处方剂量为距施源器表面5 mm处,评估CTV D90、V100及CTV最暴露2 cm³的EQD2(α/β=3)。
- 晚期毒性前瞻性评估采用RTOG膀胱和直肠评分及LENT-SOMA客观标准评估阴道晚期毒性。
主要发现
- 中位随访60个月(15.9-60)。
- 两组均无阴道残端复发及膀胱、直肠晚期毒性。
- 阴道晚期毒性≥G1:组1为26/44(59.1%),组2为25/66(37.9%)。
- CTV最暴露2 cm³平均EQD2(α/β=3):组1为63.7 Gy±10.0,组2为60.5 Gy±3.8(p=0.063)。
- 阴道扩张器使用≥9个月的依从性、总体D90和V100无差异。
关键数值与推荐
- 组1方案:6 Gy×3次,处方于距施源器表面5 mm处。
- 组2方案:7.5 Gy×2次,CTV最暴露2 cm³的EQD2(α/β=3)剂量限量为68 Gy,处方于距施源器表面5 mm处。
- 阴道晚期毒性≥G1:组1为26/44(59.1%),组2为25/66(37.9%)。
- CTV最暴露2 cm³平均EQD2(α/β=3):组1为63.7 Gy±10.0,组2为60.5 Gy±3.8(p=0.063)。
局限性
- 需更大样本系列证实当前结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare two vaginal brachytherapy (VBT) schedules in postoperative endometrial carcinoma (PEC) patients considering vaginal-cuff relapses (VCR), late toxicities, dosimetry analysis and vaginal dilator use. MATERIAL AND METHODS: 110 PEC patients were treated with exclusive high-dose-rate VBT using two schedules. Group-1:44-patients received 6 Gy×3fractions (September-2011-April-2014); Group-2:66-patients were treated with 7.5 Gy×2fractions with a dose limit of equivalent total doses in 2-Gy fr (EQD2(α/β=3)) of 68 Gy in the most exposed 2 cm3 of clinical target volume (CTV) (July-2015-November-2021). The dose was prescribed at 5 mm from the applicator surface. Were evaluated the overall radiation dose delivered to 90% of the CTV (D90), the CTV receiving 100% of the prescription dose (V100) and the EQD2(α/β=3) received in the most exposed 2 cm3 to dose in CTV. Late toxicity was prospectively assessed using RTOG scores for bladder and rectum and objective LENT-SOMA criteria for late vaginal toxicity (LVT). STATISTICS: Descriptive analysis, Chi-square, Student's t-tests and Kaplan and Meier method. RESULTS: The median follow-up was 60 months (15.9-60). There were no VCR or late toxicities in bladder or rectum. LVT ≥ G1 appeared in 26/44 (59.1%) in Group-1 and 25/66 (37.9%) in Group-2. The mean EQD2(α/β=3) received by the most exposed 2 cm3 of CTV was 63.7 Gy ± 10.0 in Group-1 and 60.5 Gy ± 3.8 in Group-2 (p = 0.063). There were no differences in adherence to vaginal dilator use ≥9 months, overall D90 and V100. CONCLUSION: Considering the lack of vaginal relapses and similar LVT over time, 7.5 Gy×2fractions seem more efficient in terms of patient comfort, workload, and cost. This is the first study using dosimetry parameters to compare effectivity of schedules. Larger series are needed to confirm the present results.
引用
- Noorian F, Abellana R, Zhang Y, et al. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis. Radiother Oncol. 2023. PMID: 37699447. doi:10.1016/j.radonc.2023.109909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。